Arcturus Therapeutics to Attend Upcoming Investor Conference Nov 24, 2025 04:01PM
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress Nov 10, 2025 04:01PM
Arcturus Therapeutics to Attend Upcoming Investor Conferences Nov 4, 2025 04:01PM
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 Oct 28, 2025 04:01PM
Arcturus reports interim data for cystic fibrosis treatment ARCT-032 Oct 22, 2025 07:30AM
View Older Stories

Oct 22, 2025 07:30AM Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
Aug 26, 2025 04:01PM Arcturus Therapeutics to Attend Upcoming Investor Conferences
Aug 11, 2025 04:01PM Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Jul 24, 2025 04:01PM Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Jul 23, 2025 04:01PM Arcturus Therapeutics to Attend Upcoming Investor Conferences
Jun 30, 2025 11:00AM Arcturus Therapeutics (ARCT) Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase Deficiency Program
Jun 30, 2025 11:00AM Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Jun 23, 2025 08:30AM Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
May 29, 2025 04:01PM Arcturus Therapeutics to Attend Upcoming Investor Conferences
May 12, 2025 04:01PM Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Apr 22, 2025 04:01PM Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Apr 10, 2025 08:00AM Arcturus Therapeutics (ARCT) Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Apr 10, 2025 08:00AM Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Mar 6, 2025 04:01PM Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Mar 5, 2025 04:30PM Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Feb 24, 2025 04:01PM Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
Feb 14, 2025 08:30AM European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Feb 14, 2025 08:00AM European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Feb 4, 2025 08:33AM Arcturus Therapeutics (ARCT) Appoints Moncef Slaoui as Chair Designate
Feb 4, 2025 08:30AM Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Jan 30, 2025 04:01PM Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Jan 10, 2025 08:00AM Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
Jan 6, 2025 04:01PM Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
Dec 16, 2024 04:01PM Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov 26, 2024 04:01PM Arcturus Therapeutics to Attend Upcoming Investor Conferences
Nov 18, 2024 08:00PM Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Nov 11, 2024 04:01PM Arcturus Therapeutics (ARCT) Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Nov 11, 2024 04:01PM Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Nov 7, 2024 04:01PM Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
Oct 31, 2024 04:01PM Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
Sep 30, 2024 08:00AM Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Sep 13, 2024 08:15AM Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Me
Sep 13, 2024 08:00AM Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan b
Sep 3, 2024 08:33AM Arcturus Therapeutics (ARCT) Receives FDA “Study May Proceed” Notice for ARCT-032
Sep 3, 2024 08:30AM Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibro
Aug 27, 2024 05:00PM Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Aug 5, 2024 04:01PM Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
Aug 1, 2024 04:01PM Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
Jul 18, 2024 07:30PM Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Jul 1, 2024 04:01PM Arcturus Therapeutics (ARCT) Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Jul 1, 2024 04:01PM Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Jun 20, 2024 08:06AM Arcturus Therapeutics (ARCT) Appoints Moncef Slaoui to its Board
Jun 20, 2024 08:00AM Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
Jun 7, 2024 10:32AM Arcturus Therapeutics (ARCT) Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
Jun 7, 2024 10:30AM Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
May 28, 2024 06:30AM Arcturus Therapeutics (ARCT) Announces Positive Development for Cystic Fibrosis Program
May 28, 2024 06:30AM Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 22, 2024 07:02AM Achilles Therapeutics (ACHL) Announces Research Collaboration with Arcturus Therapeutics (ARCT) to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024 07:00AM Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 20, 2024 08:30AM Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
View Older Stories